HWI group
Penelope Pearl Langer has been working as a Scientist Innovative Formulations at HWI Group since June 2022. Prior to that, Penelope Pearl worked as a Chemielaborant at Sofotec GmbH - A member of the AstraZeneca Group, focusing on Inhalation Product Development from July 2020 to June 2022. Before entering the pharmaceutical industry, Penelope gained experience as a Chemielaborant at Clariant from September 2017 to June 2020. Penelope Pearl completed their Chemielaborant degree at Paul-Ehrlich-Schule and obtained a Fachhochschulreife in Gestaltung from Hochtaunusschule.
This person is not in any teams
HWI group
With 150 colleagues at 3 sites in Ruelzheim, Frankfurt and Appenweier we look back on 30 years of experience. We offer a service portfolio ranging from product development, analytical development and quality control, manufacturing of clinical batches and smaller market batches to drug safety and GxP services. Together with network partners, HWI also supports clinical and preclinical studies. Our technology platform for parenteral, nasal and oral applications focuses on the development of innovative and affordable drugs with a special focus on poorly soluble small and large molcules. Our purpose is with novel technologies and innovative services to drive the development of highly effective medicines for everyone to improve peoples lives. Imprint: https://www.hwi-group.de/en/imprint.html Data protection information: https://www.hwi-group.de/en/company/infocenter.html GTC: https://www.hwi-group.de/en/company/infocenter.html